---
layout: default
title: Pravastatin
description: "Pravastatin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 9 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 137
evidence_level: L5
indication_count: 9
---

# Pravastatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>9</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pravastatin (æ™®ä¼ä»–æ±€) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pravastatin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
æ™®ä¼ä»–æ±€æ˜¯ä¸€ç¨®HMG-CoAé‚„åŸé…¶æŠ‘åˆ¶åŠ‘(ä»–æ±€é¡è—¥ç‰©),TxGNNé æ¸¬å…¶å¯ç”¨æ–¼åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡å’ŒHIVæ„ŸæŸ“ç›¸é—œè¡€è„‚ç•°å¸¸,å…©è€…å‡æœ‰è‡¨åºŠè©¦é©—å’Œæ–‡ç»è­‰æ“šæ”¯æŒ,ä¸”éƒ¨åˆ†å·²æ¥è¿‘æ ¸å‡†é©æ‡‰ç—‡ç¯„åœã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Pravastatin (æ™®ä¼ä»–æ±€) |
| DrugBank ID | DB00175 |
| å°ç£å“ç‰Œå | å¸•ç“¦æ–¯å¾·å®šéˆ‰é¹½ã€Mevalotinç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | é«˜è¡€è„‚ç—‡ã€å¿ƒè¡€ç®¡ç–¾ç—…é é˜²ã€ç§»æ¤å¾Œé«˜è„‚è¡€ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | homozygous familial hypercholesterolemiaã€obsolete familial combined hyperlipidemiaã€HIV infectious diseaseã€neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matterã€feline acquired immunodeficiency syndromeã€simian immunodeficiency virus infectionã€hyperlipoproteinemiaã€familial hypercholesterolemiaã€hypoalphalipoproteinemia |
| æœ€é«˜è­‰æ“šç­‰ç´š | L1-L2 (å¤šå€‹RCTæ”¯æŒ) |
| è‡¨åºŠè©¦é©—æ•¸ | 4é …ä»¥ä¸Š |
| æ–‡ç»æ”¯æŒ | è±å¯Œ (>13ç¯‡) |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. homozygous familial hypercholesterolemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

### åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡é æ¸¬åˆ†æ (TxGNN Score: 0.9995, Rank: 1691)

1. **ä»–æ±€é¡è—¥ç‰©æ©Ÿåˆ¶**: PravastatinæŠ‘åˆ¶HMG-CoAé‚„åŸé…¶,æ¸›å°‘è‚è‡Ÿè†½å›ºé†‡åˆæˆ
2. **å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡æ²»ç™‚**: å·²æ ¸å‡†ç”¨æ–¼å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡(heterozygous)
3. **åŒåˆå­å‹æŒ‘æˆ°**: hoFHæ‚£è€…LDLå—é«”åŠŸèƒ½åš´é‡ç¼ºé™·,å–®ä¸€ä»–æ±€ç™‚æ•ˆæœ‰é™ä½†ä»ç‚ºåŸºç¤æ²»ç™‚
4. **åˆä½µæ²»ç™‚ç­–ç•¥**: é€šå¸¸éœ€èˆ‡PCSK9æŠ‘åˆ¶åŠ‘ã€ezetimibeã€LDLè¡€æ¼¿åˆ†é›¢è¡“åˆä½µ

### HIVæ„ŸæŸ“ç›¸é—œè¡€è„‚ç•°å¸¸é æ¸¬åˆ†æ (TxGNN Score: 0.997, Rank: 5819)

1. **æŠ—ç—…æ¯’è—¥ç‰©å‰¯ä½œç”¨**: HIVè›‹ç™½é…¶æŠ‘åˆ¶åŠ‘å¸¸å°è‡´è¡€è„‚ç•°å¸¸
2. **ä»£è¬å®‰å…¨æ€§å„ªå‹¢**: Pravastatinä¸ç¶“CYP3A4ä»£è¬,èˆ‡æŠ—ç—…æ¯’è—¥ç‰©äº¤äº’ä½œç”¨å°‘
3. **è‡¨åºŠå¯¦è­‰æ”¯æŒ**: å·²æœ‰éš¨æ©Ÿå°ç…§è©¦é©—è­‰å¯¦å…¶åœ¨HIVæ‚£è€…ä¸­çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§

### è‡¨åºŠè©¦é©—

### åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ç›¸é—œè©¦é©—

| è©¦é©—ç·¨è™Ÿ | Phase | ç‹€æ…‹ | ç ”ç©¶è—¥ç‰© | èªªæ˜ |
|----------|-------|------|----------|------|
| NCT03510715 | Phase 3 | å·²å®Œæˆ | Alirocumab | å…’ç«¥é’å°‘å¹´hoFH,èƒŒæ™¯ä»–æ±€æ²»ç™‚ |

**NCT03510715è©¦é©—é‡é»**:
- 8-17æ­²hoFHæ‚£è€…
- åœ¨ä»–æ±€é¡(å«pravastatin)+/-å…¶ä»–é™è„‚è—¥åŸºç¤ä¸ŠåŠ ç”¨alirocumab
- è­‰å¯¦åˆä½µç™‚æ³•çš„å¯è¡Œæ€§

### HIVæ„ŸæŸ“ç›¸é—œè¡€è„‚ç•°å¸¸è©¦é©—

| è©¦é©—ç·¨è™Ÿ | Phase | ç‹€æ…‹ | è¨­è¨ˆ | å—è©¦è€…æ•¸ |
|----------|-------|------|------|----------|
| NCT00982189 | N/A | å·²å®Œæˆ | Polypillé é˜²ç ”ç©¶ | 37äºº |
| NCT00227500 | Phase 4 | å·²å®Œæˆ | éš¨æ©Ÿé›™ç›²å°ç…§ | 40äºº |
| NCT00017758 | Phase 1 | å·²å®Œæˆ | è—¥å‹•å­¸äº¤äº’ä½œç”¨ç ”ç©¶ | 56äºº |

**NCT00227500è©¦é©—é‡é»**:
- éš¨æ©Ÿã€å®‰æ…°åŠ‘å°ç…§ç ”ç©¶
- HIVæ„ŸæŸ“åˆä½µè›‹ç™½é…¶æŠ‘åˆ¶åŠ‘ä½¿ç”¨çš„é«˜è†½å›ºé†‡è¡€ç—‡æ‚£è€…
- ä¸»è¦çµ‚é»: ç©ºè…¹ç¸½è†½å›ºé†‡çš„æ™‚é–“åŠ æ¬Šè®ŠåŒ–
- è­‰å¯¦pravastatinåœ¨HIVæ‚£è€…ä¸­çš„é™è„‚æ•ˆæœ

**NCT00017758è©¦é©—é‡é»**:
- è©•ä¼°efavirenzå’Œnelfinavirå°pravastatinè—¥å‹•å­¸çš„å½±éŸ¿
- ç¢ºèªpravastatinèˆ‡æŠ—ç—…æ¯’è—¥ç‰©çš„äº¤äº’ä½œç”¨ç‰¹æ€§

### ç›¸é—œæ–‡ç»

### åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ç›¸é—œæ–‡ç» (>13ç¯‡)

| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | ä¸»è¦ç™¼ç¾ |
|------|------|----------|----------|
| 28437620 | 2017 | æŒ‡å¼• | AACE/ACEè¡€è„‚ç•°å¸¸ç®¡ç†æŒ‡å¼• |
| 28685504 | 2017 | Cochraneç³»çµ±æ€§å›é¡§ | å…’ç«¥FHçš„ä»–æ±€é¡è—¥ç‰©æ²»ç™‚ |
| 31696945 | 2019 | Cochraneç³»çµ±æ€§å›é¡§æ›´æ–° | ç¢ºèªä»–æ±€åœ¨å…’ç«¥FHçš„è§’è‰² |
| 12269853 | 2002 | è—¥ç‰©è©•è«– | Rosuvastatinèˆ‡pravastatinæ¯”è¼ƒ |

**é—œéµç™¼ç¾**:
- ä»–æ±€é¡è—¥ç‰©æ˜¯å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡çš„åŸºç¤æ²»ç™‚
- å…’ç«¥æœŸé–‹å§‹æ²»ç™‚å¯é™ä½é•·æœŸå¿ƒè¡€ç®¡é¢¨éšª
- hoFHéœ€å¤šé‡ç™‚æ³•åˆä½µ,å–®ä¸€ä»–æ±€æ•ˆæœæœ‰é™

### HIVç›¸é—œè¡€è„‚ç•°å¸¸æ–‡ç»

| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | ä¸»è¦ç™¼ç¾ |
|------|------|----------|----------|
| 28416195 | 2017 | Phase 4 RCT | Pitavastatin vs Pravastatinåœ¨HIVæ‚£è€…(INTREPIDè©¦é©—) |

**INTREPIDè©¦é©— (PMID: 28416195)é‡é»**:
- å¤šä¸­å¿ƒã€éš¨æ©Ÿã€é›™ç›²ã€52é€±è©¦é©—
- HIV-1æ„ŸæŸ“åˆä½µè¡€è„‚ç•°å¸¸æ‚£è€…
- Pravastatinå› ä¸ç¶“CYP3A4ä»£è¬,è—¥ç‰©äº¤äº’ä½œç”¨é¢¨éšªä½
- Pitavastatiné™LDLæ•ˆæœå„ªæ–¼pravastatin

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. HIV infectious disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.74%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.74%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.62%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.62%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. feline acquired immunodeficiency syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.55%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. simian immunodeficiency virus infection</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.55%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. familial hypercholesterolemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.34%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.34%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hypoalphalipoproteinemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.21%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.07%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. cholesterol-ester transfer protein deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.04%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.04%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### æœ‰æ•ˆè¨±å¯è­‰

å°ç£å·²æœ‰å¤šé …pravastatinè£½åŠ‘æ ¸å‡†,æ ¸å‡†é©æ‡‰ç—‡åŒ…æ‹¬:

1. **é«˜è¡€è„‚ç—‡**: åŸç™¼æ€§é«˜è†½å›ºé†‡è¡€ç—‡ã€æ··åˆå‹é«˜è¡€è„‚ç—‡
2. **åˆç™¼æ€§é é˜²**: é«˜è†½å›ºé†‡è¡€ç—‡ç„¡å† å¿ƒç—…æ‚£è€…çš„å¿ƒè‚Œæ¢—å¡é é˜²
3. **å†ç™¼æ€§é é˜²**: å† å¿ƒç—…æ‚£è€…çš„äºŒæ¬¡é é˜²
4. **ç§»æ¤å¾Œé«˜è„‚è¡€ç—‡**: å¿ƒè‡Ÿç§»æ¤å¾Œå…ç–«æŠ‘åˆ¶æ²»ç™‚ç›¸é—œé«˜è„‚è¡€ç—‡

### é‡è¦èªªæ˜
å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡å·²åœ¨éƒ¨åˆ†è£½åŠ‘æ ¸å‡†é©æ‡‰ç—‡ä¸­æåŠã€‚

## å®‰å…¨æ€§è€ƒé‡

### å·²çŸ¥å®‰å…¨æ€§è³‡è¨Š

1. **è‚Œè‚‰æ¯’æ€§**: ç½•è¦‹ä½†å¯èƒ½ç™¼ç”Ÿæ©«ç´‹è‚Œæº¶è§£ç—‡
2. **è‚åŠŸèƒ½ç•°å¸¸**: éœ€ç›£æ¸¬è‚åŠŸèƒ½æŒ‡æ•¸
3. **ç³–å°¿ç—…é¢¨éšª**: é•·æœŸä½¿ç”¨å¯èƒ½è¼•å¾®å¢åŠ ç³–å°¿ç—…é¢¨éšª
4. **è—¥ç‰©äº¤äº’ä½œç”¨**: èˆ‡éƒ¨åˆ†è—¥ç‰©æœ‰äº¤äº’ä½œç”¨,ä½†ç¨‹åº¦è¼ƒå…¶ä»–ä»–æ±€è¼•

### HIVæ‚£è€…ç‰¹æ®Šè€ƒé‡

1. **CYPä»£è¬å„ªå‹¢**: Pravastatinä¸ç¶“CYP3A4ä»£è¬
2. **èˆ‡æŠ—ç—…æ¯’è—¥ç‰©äº¤äº’ä½œç”¨**:
   - èˆ‡è›‹ç™½é…¶æŠ‘åˆ¶åŠ‘äº¤äº’ä½œç”¨è¼ƒå°‘
   - Lopinavir/ritonavirå¯èƒ½å¢åŠ pravastatinè¡€ä¸­æ¿ƒåº¦
3. **ç›£æ¸¬å»ºè­°**: ä»éœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½å’Œè‚Œé…¸æ¿€é…¶

### è—¥ç‰©äº¤äº’ä½œç”¨é‡é»

- èˆ‡fibratesä½µç”¨å¢åŠ è‚Œç—…é¢¨éšª
- èˆ‡å…ç–«æŠ‘åˆ¶åŠ‘(ciclosporin)äº¤äº’éœ€è¬¹æ…
- èˆ‡æŠ—å‡è¡€åŠ‘éœ€ç›£æ¸¬INR

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šConcomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.
- å»ºè­°ï¼šPatients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients...



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Cognitive Dysfunction** ğŸŸ¡ Moderate
- Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of p...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug met...

**Rhabdomyolysis** ğŸŸ¢ Minor
- Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakne...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°

| è©•ä¼°é …ç›® | åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ | HIVç›¸é—œè¡€è„‚ç•°å¸¸ |
|----------|--------------------------|------------------|
| è­‰æ“šç­‰ç´š | L2 (ç³»çµ±æ€§å›é¡§æ”¯æŒ) | L1-L2 (å¤šå€‹RCT) |
| æ©Ÿåˆ¶åˆç†æ€§ | é«˜ (å·²ç‚ºåŸºç¤æ²»ç™‚) | é«˜ (ä»£è¬å„ªå‹¢) |
| è‡¨åºŠå¯è¡Œæ€§ | é«˜ (åˆä½µç™‚æ³•ä¸€éƒ¨åˆ†) | é«˜ |
| å»ºè­°å„ªå…ˆé †åº | é«˜ | é«˜ |

### å»ºè­°

**åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡**:
1. **è‡¨åºŠå®šä½**: ä½œç‚ºhoFHå¤šé‡ç™‚æ³•çš„åŸºç¤æ²»ç™‚
2. **åˆä½µç”¨è—¥**: éœ€èˆ‡PCSK9æŠ‘åˆ¶åŠ‘ã€ezetimibeç­‰åˆä½µ
3. **é©æ‡‰ç—‡æ“´å±•**: è€ƒæ…®åœ¨ç¾æœ‰å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡é©æ‡‰ç—‡ä¸‹åŒ…å«hoFH

**HIVç›¸é—œè¡€è„‚ç•°å¸¸**:
1. **é¦–é¸ä»–æ±€ä¹‹ä¸€**: å› ä»£è¬ç‰¹æ€§,ç‚ºHIVæ‚£è€…è¼ƒå®‰å…¨çš„ä»–æ±€é¸æ“‡
2. **è‡¨åºŠæ¨å»£**: å¯åœ¨æŠ—ç—…æ¯’æ²»ç™‚ç›¸é—œè¡€è„‚ç•°å¸¸æŒ‡å¼•ä¸­æ¨è–¦
3. **è—¥å‹•å­¸å„ªå‹¢**: ç‰¹åˆ¥é©ç”¨æ–¼ä½¿ç”¨CYP3A4æŠ‘åˆ¶åŠ‘å‹æŠ—ç—…æ¯’è—¥ç‰©çš„æ‚£è€…

### å¯¦å‹™å»ºè­°

1. **ç›£æ¸¬è¨ˆç•«**:
   - åŸºç·šå’Œæ²»ç™‚æœŸé–“å®šæœŸç›£æ¸¬è‚åŠŸèƒ½ã€CK
   - HIVæ‚£è€…æ³¨æ„ç—…æ¯’è¼‰é‡å’ŒCD4è®ŠåŒ–

2. **åŠ‘é‡è€ƒé‡**:
   - HIVæ‚£è€…å¯èƒ½éœ€è¼ƒä½èµ·å§‹åŠ‘é‡
   - æ ¹æ“šé™è„‚æ•ˆæœèª¿æ•´åŠ‘é‡

### é™åˆ¶èªªæ˜

- hoFHæ‚£è€…å› LDLå—é«”ç¼ºé™·,ä»–æ±€å–®ä¸€ç™‚æ³•æ•ˆæœæœ‰é™
- Pravastatiné™è„‚æ•ˆåŠ›ä¸å¦‚å…¶ä»–é«˜æ•ˆä»–æ±€(å¦‚atorvastatin, rosuvastatin)
- HIVæ‚£è€…çš„å¿ƒè¡€ç®¡é å¾Œé•·æœŸæ•¸æ“šä»åœ¨ç´¯ç©ä¸­

---
*å ±å‘Šç”¢ç”Ÿæ—¥æœŸ: 2026-02-11*
*è³‡æ–™ä¾†æº: TxGNNé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£é£Ÿå“è—¥ç‰©ç®¡ç†ç½²*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nepafenac]({{ "/drugs/nepafenac/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pimozide]({{ "/drugs/pimozide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Bempedoic Acid]({{ "/drugs/bempedoic_acid/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Homatropine Methylbromide]({{ "/drugs/homatropine_methylbromide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pravastatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pravastatin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pravastatin,
  title = {Pravastatinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pravastatin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
